PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Share Price Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.95 EUR | 0.00% |
|
+1.20% | -35.87% |
| Sales 2024 * | 1.05M 1.12M 89.9M | Sales 2025 * | 1.6M 1.71M 137M | Capitalization | 17.92M 19.16M 1.53B |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | 1M 1.07M 85.62M | EV / Sales 2024 * | 17.5 x |
| Net Debt 2024 * | 450K 481K 38.53M | Net Debt 2025 * | 10.55M 11.28M 903M | EV / Sales 2025 * | 17.8 x |
| P/E ratio 2024 * |
-2.09
x | P/E ratio 2025 * |
-3.11
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.14% |
More Fundamentals
* Assessed data
More news
Latest transcript on PHAXIAM Therapeutics S.A.
More press releases
More news
| 1 week | +1.03% | ||
| Current month | -1.01% | ||
| 1 month | +1.72% | ||
| 3 months | -28.05% | ||
| 6 months | -33.41% | ||
| Current year | -35.87% |
1 week
2.88
2.95
1 month
2.853.00
3 years
2.6075.80
5 years
2.60114.60
10 years
2.60402.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 22/06/23 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 22/06/23 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 22/06/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 22/06/23 | |
Hilde Windels
BRD | Director/Board Member | 59 | 22/06/23 |
Gil Beyen
BRD | Director/Board Member | 62 | 22/06/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2.95 | 0.00% | 16,261 |
| 25/04/24 | 2.95 | +1.20% | 941 |
| 24/04/24 | 2.915 | -0.17% | 1,540 |
| 23/04/24 | 2.92 | -0.68% | 1,047 |
| 22/04/24 | 2.94 | +0.68% | 731 |
Real-time Euronext Paris, April 26, 2024 at 04:35 pm
More quotes
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
14/05/2024
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.95
EUR
Average target price
6.85
EUR
Spread / Average Target
+132.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
